These theories have led to the development of increased dosage regimens, high-intensity dosing, more frequent-dosing regimens, high-dose myelo-ablative chemotherapy with cellular re-infusion methods, and the use of multiple agent chemotherapy regimens.
Tumor response rates for single or multiple agent chemotherapy regimens were low without durable remission leading to a 1-year survival between 0% to 30% [ 10].
Most likely, youth on more intensive regimens, e.g., insulin or multiple agents, had already failed less intensive regimens.
Optimal breast cancer chemotherapy regimens include multiple agents, some with known cardiac side effects.
Modern oncological treatment regimens often incorporate multiple agents whose deleterious effects might be additive or synergistic, making their identification and treatment more challenging.
If chemotherapy regimens consisted of multiple agents, the treatment arms under comparison could only differ in the presence or absence of an anthracycline or type of anthracycline such that the other therapies being compared were the same between groups.
This reflected trial design and clinical practice at a time when HER2-targeted therapy was not routinely continued in combination with successive chemotherapy regimens and there were not multiple agents targeting the HER family.
In these situations complex treatment regimens are used which often involve multiple agents that are capable of affecting cytochrome P450 enzymes.
On-treatment biopsies to test for target engagement or other pharmacodynamic markers are desirable but not uniformly feasible across studies, particularly in the setting of combination regimens for which a validated measure of the complex interplay of multiple agents may not be available.
Therefore, regimens with doses considered adequate but not at maximum dose levels of multiple agents may be sufficient for NSCLC patients, including the elderly.
